Macrogenics Inc Stock Price, News & Analysis

Gilead Sciences (NASDAQ: GILD) has secured an exclusive option for the MGD024 molecule, a bispecific antibody targeting CD123 and CD3, through a collaboration with MacroGenics (NASDAQ: MGNX). This molecule aims to treat blood cancers such as acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Gilead has committed $60 million upfront, with a total potential of $1.7 billion in milestones. The Phase 1 study will assess MGD024's efficacy and safety while Gilead may opt to license it at set decision points.

MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company specializing in innovative cancer therapeutics, will present at three key investor conferences this September 2022. CEO Scott Koenig, M.D., Ph.D., will participate in the Citi 17th Annual BioPharma Conference on September 7 at 2:40 pm ET, the H.C. Wainwright 24th Annual Global Investment Conference on September 12 at 10:30 am ET, and the Guggenheim Nantucket Therapeutics Conference on September 28 at 2:30 pm ET. Webcasts will be available on the company's website.

MacroGenics (MGNX) has announced critical developments, including the initiation of a Phase 1 study for MGD024 in CD123-positive hematologic malignancies and plans for a Phase 2/3 study of MGC018 in metastatic castration-resistant prostate cancer by year-end. Financially, the company recorded a net loss of $41.3 million for Q2 2022 and total revenue of $26 million, down from $30.8 million year-over-year. A restructuring plan aims to extend the cash runway into 2024, supported by recent $30 million milestone payments from Incyte.

MacroGenics, a biopharmaceutical firm specializing in monoclonal antibody-based therapeutics for cancer treatment, will announce its second-quarter 2022 financial results on August 8, 2022, after market closure. A conference call to discuss these results and corporate progress will follow at 4:30 PM ET on the same day. Interested participants can register for the call and access a webcast on the company's Investor Relations website. MacroGenics aims to leverage its innovative technology platforms to develop promising therapeutics and engage in strategic collaborations.

MacroGenics, Inc. (NASDAQ: MGNX) announced the closure of its Phase 2 study evaluating enoblituzumab in combination with either retifanlimab or tebotelimab for advanced head and neck cancer treatment, effective July 7, 2022. This decision followed an internal safety review revealing seven fatalities, with a higher incidence of hemorrhagic events than the literature reports. While most fatalities were attributed to disease progression, the finding raised safety concerns. The company continues to monitor these events while emphasizing participant safety and ongoing studies with other candidates.

MacroGenics, a biopharmaceutical company focused on antibody-based cancer therapeutics, will participate in the JMP Securities Life Sciences Conference on June 16, 2022, at 12:00 pm ET. The management will engage in a fireside chat and one-on-one meetings with investors. A webcast will be available on MacroGenics' website under the Investor Relations section, with an archived replay accessible for 30 days post-event. This participation highlights MacroGenics' commitment to advancing innovative cancer treatments through strategic collaborations and proprietary technology platforms.

MacroGenics, Inc. (NASDAQ: MGNX) announced the appointment of William Heiden as Chair of the Board of Directors effective May 22, 2022, following Paulo F. Costa's term expiration. Heiden brings 35 years of experience in the biotech industry and has a track record of success, including leading AMAG Pharmaceuticals to a $650 million acquisition. The board now includes eight directors, seven of whom are independent. Heiden's expertise is expected to guide MacroGenics' ongoing development of innovative cancer therapies amidst challenging market conditions.

MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company specializing in antibody-based cancer therapies, has announced its participation in the H.C. Wainwright Global Investment Conference. The event will take place on May 25, 2022, in Miami, FL, where President & CEO Scott Koenig will provide a corporate overview at 11:30 am ET. The company will also conduct one-on-one meetings with investors. A webcast of the presentation will be available on MacroGenics' Investor Relations website for 30 days following the event.

MacroGenics (NASDAQ: MGNX) reported Q1 2022 results, revealing a net loss of $66.4 million, up from $51.3 million in Q1 2021. Revenue declined to $11.1 million from $16.9 million year-over-year. The company is preparing to start a Phase 2/3 prostate cancer study with MGC018 by the end of 2022 and has initiated a Phase 1 study of MGC018 in combination with lorigerlimab for advanced solid tumors. Cash reserves fell to $184 million from $243.6 million, with guidance indicating sufficient funds through 2023 for ongoing projects.